The Promise of Technology to Advance Rigorous Evaluation of Adolescent Pregnancy Prevention Programs in American Indian and Alaska Native Tribal Communities.

Am J Public Health

Carol E. Kaufman, Kirsten Black, and Ellen M. Keane are with the Centers for American Indian and Alaska Native Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora. Traci M. Schwinn is with the School of Social Work, Columbia University, New York, NY. Cece

Published: September 2016


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049466PMC
http://dx.doi.org/10.2105/AJPH.2016.303335DOI Listing

Publication Analysis

Top Keywords

promise technology
4
technology advance
4
advance rigorous
4
rigorous evaluation
4
evaluation adolescent
4
adolescent pregnancy
4
pregnancy prevention
4
prevention programs
4
programs american
4
american indian
4

Similar Publications

Arthroplasty surgery is a common and successful end-stage intervention for advanced osteoarthritis. Yet, postoperative outcomes vary significantly among patients, leading to a plethora of measures and associated measurement approaches to monitor patient outcomes. Traditional approaches rely heavily on patient-reported outcome measures (PROMs), which are widely used, but often lack sensitivity to detect function changes (e.

View Article and Find Full Text PDF

Biodegradation of patulin in apple juice by phosphoribosyl transferase (URA5): implications for food safety.

BMC Biotechnol

September 2025

Faculty of Science, Department of Biotechnology and Food Technology, University of Johannesburg, P.O. Box 17011, Doornfontein, Johannesburg, Gauteng, 2028, South Africa.

Patulin (PAT), a mycotoxin produced primarily by Penicillium expansum, poses significant health risks and frequently contaminates apples and apple-derived products, often exceeding permissible safety limits. This study investigated the potential of orotate phosphoribosyl transferase (URA5) to degrade PAT in apple juice under controlled conditions. PAT degradation was assessed at initial concentrations of 100 µg/L and 250 µg/L, with enzymatic treatment using 0.

View Article and Find Full Text PDF

Background: The increasing amount of data routinely collected on ICUs poses a challenge for clinicians which is aggravated with data-heavy therapies like Continuous Kidney Replacement Therapy (CKRT). We developed the CKRT Supporting Software Prototype (CKRT-SSP), a clinical decision support system for use before, during and after CKRT. The aim of this user experience (UX) study was to prospectively evaluate CKRT-SSP in terms of usability, user experience, and workload in a simulated ICU setting.

View Article and Find Full Text PDF

Impact of Flow Restrictors on Aerosol Delivery of the Respimat® Soft Mist Inhaler.

Pulm Ther

September 2025

Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216, Ingelheim am Rhein, Germany.

Introduction: The modification of an inhaler's air flow resistance influences a patient's inhalation flow profile, thereby affecting the exit velocity of an aerosol leaving the Respimat® mouthpiece. A slower inhalation maneuver results in reduced plume velocity and thus a decreased oropharyngeal deposition due to reduced impaction. This could not only lead to fewer unwanted side effects associated with inhaled therapies, but also enhance lung deposition.

View Article and Find Full Text PDF

Inflammatory gene expression profile of oral plasmablastic lymphoma.

Virchows Arch

September 2025

Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Minas Gerais, Av. Antônio Carlos, Pampulha, Belo Horizonte, 31270-901, Brazil.

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs).

View Article and Find Full Text PDF